The increased energy expenditure is accompanied by an improvement of glucose intolerance, highlighting the potential of LETMD1 as a new therapeutic target for obesity and metabolic diseases. This evidence concerns the gene LETMD1 and obesity due to melanocortin 4 receptor deficiency.